Aflibercept shows efficacy in real-world treatment of age-related macular degeneration and choroidal vasculopathy

The combination of aflibercept with a treat-and-extend (TnE) regimen has demonstrated efficacy in the real-world treatment of neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), according to a study. Over a 2-year period, the treatment resulted in improved best-corrected visual acuity (BCVA), and the treatment interval could be extended to ≥16 weeks in a significant percentage of cases.

Among the 43 enrolled patients, 24 were diagnosed with nAMD, and 19 with PCV. The mean BCVA improved from 0.75 ± 0.41 at baseline to 0.60 ± 0.41 (P = 0.002) at 3 months and further to 0.66 ± 0.46 at 24 months (P = 0.137). Over the 2-year treatment period, the average number of injections was 10.95 ± 3.65. At the 24-month mark, the TnE regimen allowed an extension of the treatment interval to ≥ 16 weeks in 60.5% of all cases and 78.9% of PCV cases. Following 3 loading injections, the presence of persistent subretinal fluid and intraretinal fluid emerged as predictive factors for more frequent injections (P = 0.026) and poorer visual outcomes (P = 0.050), respectively.

Reference
Huang CH, Lai TT, Yang CH, Hsieh YT. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmol Ther. 2023;doi: 10.1007/s40123-023-00850-6. Epub ahead of print. PMID: 37995014.